BACKGROUND: The effect of angiotensin II receptor blockers on right ventricular (RV) function is still unknown. Angiotensin II receptor blockers are beneficial in patients with acquired left ventricular dysfunction, and recent findings have suggested a favorable effect in symptomatic patients with systemic RV dysfunction. The current study aimed to determine the effect of losartan, an angiotensin II receptor blocker, on subpulmonary RV dysfunction in adults after repaired tetralogy of Fallot.
T
he population of adults with congenital heart disease (CHD) is increasing because of major improvements in surgery and medical management. 1 Most patients with CHD are now expected to reach adulthood after surgery, usually with few or no symptoms. 2, 3 Nonetheless, many asymptomatic patients have right ventricular (RV) dysfunction accompanied by decreased exercise capacity and arrhythmias. [4] [5] [6] Consequently, these patients are at risk for progression into heart failure, especially in the setting of progressive RV dysfunction. Heart failure has become a major threat in aging patients with CHD, causing approximately one third of mortality. [7] [8] [9] Therefore, prevention and treatment of heart failure is considered a top priority in patients who have adult CHD (ACHD) with RV dysfunction. 10 Unfortunately, randomized studies on various treatment modalities for RV dysfunction in ACHD are limited. 11, 12 This may be explained by heterogeneity of the population and limited patient numbers, which hamper the possibility of trials on clinical end points. However, many patients with ACHD with symptomatic RV failure are treated using reninangiotensin-aldosterone system (RAAS) inhibitors based on research in acquired left ventricular (LV) dysfunction. 13 Similar to LV dysfunction, RV dysfunction leads to neurohormonal activation, even in asymptomatic patients. 4, 14, 15 Neurohormonal activation affects collagen turnover, contributing to the progression of diffuse myocardial fibrosis, hypertrophy, and further RV deterioration. 14, [16] [17] [18] [19] Indeed, in symptomatic patients with systemic RV dysfunction, a treatment effect on RV ejection fraction (EF) with angiotensin II receptor blocker treatment was found. 20 The aim of the present study is to evaluate the effect of losartan, an angiotensin II receptor blocker, on subpulmonary RV dysfunction. Patients with repaired tetralogy of Fallot (rTOF) form a relatively large and homogeneous ACHD group. 11, 21 In these patients, RV dysfunction may be secondary to volume and pressure overload, childhood cyanosis, ischemia, and scarring attributable to surgical correction. [22] [23] [24] Even after pulmonary valve replacement to reduce volume or pressure overload, many patients have incomplete RV remodeling. 23 Incomplete RV remodeling is characterized by persistent RV dysfunction and fragmentation of QRS complexes, and is associated with progressive RV failure. 23, 25, 26 The REDEFINE trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) was set up to study the effect of 18 to 24 months of RAAS inhibition, using 150 mg losartan, 27 on RV dysfunction in adults with rTOF.
METHODS

Trial Design
The REDEFINE trial was a prospective, multicenter, doubleblind, parallel, 1:1 randomized, placebo-controlled trial with 18 to 24 months follow-up. The methods were described in detail in the trial design article. 28 The data, analytic methods, and study materials will be made available to other researchers on request for purposes of reproducing the results or replicating the procedure. In brief, according to the primary hypothesis, losartan would improve RV EF in comparison with placebo, as measured by cardiovascular magnetic resonance (CMR) imaging. Losartan was chosen as opposed to an angiotensin-converting enzyme inhibitor because of fewer side effects such as cough. 29 Treatment duration was chosen because angiotensin II receptor blocker treatment improved LV EF after 18 months by ≈4% in patients without an angiotensin-converting enzyme inhibitor. 30 Two small changes were made in the trial design after the first patient was enrolled: (1) patients using mineralocorticoid receptor antagonist were allowed to be included; and (2) trial duration was slightly changed from a target of 2 years to 18 to 24 months of follow-up, because of the logistical planning of follow-up examinations. This study complied with the Declaration of Helsinki and was approved by the medical ethics committees of all 6 participating centers. All patients provided informed consent for participation in this study.
Participants
Adult patients with rTOF were identified via the Congenital Corvitia (CONCOR) database, a Dutch national registry of patients with ACHD. 31 Adults with rTOF were eligible if RV
Clinical Perspective
What Is New?
• No evidence-based treatment is available for subpulmonary right ventricular dysfunction in adult patients with congenital heart disease.
• This is the first trial to study the effects of reninangiotensin-aldosterone system inhibitors in adults with tetralogy of Fallot with mild right ventricular (RV) dysfunction in the absence of severe valvular lesions.
• This is the largest trial to study renin-angiotensinaldosterone system inhibition in patients with RV dysfunction in the setting of adult congenital heart disease.
What Are the Clinical Implications?
• Losartan did not improve RV dysfunction or any clinically relevant secondary outcomes in adults with repaired tetralogy of Fallot and mild RV dysfunction.
• Losartan should not be prescribed routinely in these patients to prevent the progression of RV dysfunction and RV heart failure. ) and no severe valvular lesions (ie, pulmonary regurgitation on CMR <40%, pulmonary stenosis peak gradient <64 mm Hg, tricuspid regurgitation not more than moderate on echocardiography 33, 34 ) were present. Patients using RAAS inhibition were eligible only if treatment was stopped at least 4 weeks before baseline examinations were performed, and those with a strict indication such as LV failure were excluded from participation. A complete list of inclusion and exclusion criteria is provided in Table I in the online-only Data Supplement.
Interventions, Randomization, and Blinding
Patients were randomly assigned 1:1 by the unblinded hospital pharmacy to losartan (50 mg tablets) or matching placebo by block randomization. 28 Patients, study personnel, and caregivers were all blinded to treatment. Patients started at a dose of 50 mg once daily and were uptitrated to the target dose of 150 mg once daily within 4 weeks. Dose was adjusted if side effects occurred or abnormalities were found during routine laboratory investigations (renal function, liver function parameters, electrolytes). A dose of 150 mg once daily was chosen based on its prognostic effect in LV failure.
27
Outcomes
Study outcomes were obtained in all participating patients at baseline and after 18 to 24 months of treatment. The primary outcome was change in RV EF after treatment. Secondary outcomes included change in RV and LV volumes and mass, LV EF, peak exercise capacity (percent of predicted in Watts/peak Vo 2 [maximum achieved oxygen consumption]), serum N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, and quality of life. A composite clinical outcome supraventricular tachycardia requiring intervention, ventricular tachycardia (≥4 beats), heart failure requiring increase of diuretics, or increase in New York Heart Association class was obtained to explore potential clinical benefits. Safety outcomes included the rate of reported adverse events, electrolytes, renal and liver function abnormalities, and drug discontinuation.
CMR
CMR imaging acquisition was performed with locally available scanners and was described in more detail in the trial design article. 28 Endocardial and epicardial contours were delineated by a single observer (J.P.B.). Trabeculations and papillary muscles were considered part of the ventricular cavity. 28, 35 Cardiac volumes, EF, and mass were calculated according to standard methods as previously detailed. Intraobserver variability was previously reported. 28 
Other Measurements
Echocardiography was used to determine RV outflow tract gradient, restrictive physiology (late diastolic forward flow in the pulmonary artery), and tricuspid regurgitation grade, as previously detailed. 28 Cardiopulmonary exercise testing was performed to assess Vo 2 during aerobic exercise (percentage of predicted). Alternatively, in patients with an incomplete measurement of Vo 2 , the percentage of predicted workload was obtained. Laboratory measurements (renal function, liver function parameters, electrolytes, NT-proBNP) were performed before the start of the study. Laboratory measurements were repeated during and after the trial according to a predefined schedule. 28 A standard 12-lead ECG was acquired before and after treatment to assess QRS duration and presence of QRS fragmentation, defined as notches in the QRS complex in ≥2 contiguous leads, not related to bundle-branch block. 25 Quality of life was assessed by using the Medical Outcomes Study 36-Item Short Form (SF-36). 36 
Sample Size
Sample size calculation was based on the primary end point change in RV EF in the intention-to-treat analysis. Based on a SD of 5% of RV EF change, 90 patients were required (with available preoperative and postoperative CMR) to detect a difference of 3% between 2 treatment groups (2-sided α of 0.05, 80% power).
Statistical Methods
Statistical methods and end points were previously specified in the trial protocol and design article. 28 For statistical analyses, SPSS 24.0 (SPSS Inc) for Windows was used. A P value of <0.05 was considered statistically significant. The effect of losartan on RV EF change in the intention-to-treat analysis was evaluated by covariance analysis with baseline RV EF as covariate. The effect of losartan on secondary outcomes was evaluated similarly, with baseline values as covariates. NT-proBNP was log-transformed to achieve normality. In addition, on-treatment analyses were performed, excluding patients who discontinued trial medication prematurely. Differences between baseline and follow-up measurements within groups were assessed using a paired t test or MannWhitney U test, as appropriate. Between-group differences in binary outcomes were assessed by using the Fisher exact test. Covariate by treatment group interaction tests were performed to detect differences in treatment effects between predefined subgroups.
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RESULTS
A total of 100 adult patients with rTOF were randomly assigned between losartan and placebo ( Figure 1 ). Of 95 patients who started treatment, 47 patients were randomly assigned to losartan treatment (age, 38.0±12.4 years; 74% male; baseline RV EF, 45.6%; interquartile range, 42.8-48.2) and 48 patients received placebo (age, 40.6±11.4 years; 63% male; baseline RV EF, 45.2%; interquartile range, 42.4-47.5). Baseline characteristics are listed in Table 1 . Patients were treated for 21±4 months. Follow-up duration was similar in both treatment arms. Ten (21%) patients in the losartan arm and 7 (15%) in the placebo arm prematurely discontinued trial medication (see Figure 1 for reasons) (P=0.43). The primary end point could be evaluated in 88 patients (93%). In 7 patients, there was no CMR
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performed after baseline examination or CMR was incomplete (see Figure 1 for reasons); 6 of these patients were among the 17 patients who prematurely discontinued study medication. In the remaining 11 patients who prematurely discontinued study medication, CMR was performed as planned 18 to 24 months after inclusion and thus after discontinuation of medication.
Primary End Point
Overall, RV EF remained unchanged in patients allocated to losartan (n=42 (Figures 2 and 3A) . The on-treatment analysis (n=77) revealed similar results (-0.05%; 95% CI, -1.6 to +1.5; P=0.95).
Secondary End Points
As expected, losartan lowered systolic blood pressure in comparison with placebo (-8.8 mm Hg; 95% CI, -14 to -3.4). Overall, losartan had no treatment effect on RV end-diastolic volume, LV EF, and LV end-diastolic volume ( Figure 2 ). Losartan decreased LV mass in comparison with placebo (-5.0 g; 95% CI, -9.5 to -0.4; P=0.034), especially in patients with higher LV mass before treatment (P for interaction, 0.027). Change in LV mass was not related to systolic blood pressure reduction (Pearson correlation R=0.00, P=0.98). At baseline, patients with rTOF had a decreased Vo 2 max (peak oxygen consumption)/exercise capacity (80.6±16.7% of predicted in losartan, 82.4±20.1 of predicted in placebo). Losartan treatment had no effect on peak Vo 2 (+1.9% of predicted; 95% CI, -2.6 to 6.4; P=0.40). A total of 58 patients (66%) had increased NT-proBNP (>86 pg/mL) at baseline examination. However, losartan had no treatment effect on NT-proBNP (P=0.62) (Figure 2 ).
Subgroup Analyses
Our predefined subgroup analyses focused on patients with symptoms, restrictive physiology, moderate (<40%) RV dysfunction, QRS fragmentation, and previous pulmonary valve replacement revealed no significant treatment effects (Figure 4) . Similarly, in subgroups of NTproBNP elevation, moderate (20%-40%) pulmonary regurgitation, and age>40 years, no significant treatment effects were found. Of note, in 13 symptomatic patients (New York Heart Association II), a nonsignificant trend toward a positive treatment effect of +2.2% on RV EF was found in comparison with placebo (P=0.38). In addition, these symptomatic patients had a nonsignificant effect of losartan on LV EF (+5.6%, P=0.085). In an exploratory analysis, losartan improved RV EF in the subgroup (n=30, losartan/placebo=15/15) with nonrestrictive RV and incomplete remodeling (combination of QRS fragmentation, nonrestrictive RV, and previous pulmonary valve replacement) (+2.7% in comparison with placebo, P=0.045) ( Figures 3B and 4) . In addition, in this group, losartan had a nonsignificantly favorable effect on LV EF (+3.4%, P=0.076), whereas no effects on oth- 
Adverse Events
Adverse events were reported in 21 (45%) patients allocated to losartan and in 14 (29%) allocated to placebo (P=0.14) ( Table 2 ). Serious adverse events (requiring nonelective hospitalization) occurred in 2 (4%) patients allocated to losartan and 4 (8%) with placebo (P=0.68), but were mostly (4 of 6) for noncardiac reasons. A total of 4 patients in the losartan arm discontinued trial medication because of kidney (n=2) or liver dysfunction (n=2), although these patients recovered after discontinuation. Other reasons for premature trial discontinuation are listed in Figure 1 . The final achieved daily dose was similar in both groups (Table 2) .
Clinical Events
None of the patients died during the 21±4 months of follow-up. Seven patients (15%) in both treatment arms experienced the composite clinical end point; 2 of them had multiple events. Of 5 patients with supraventricular tachycardia, electric cardioversion was performed in 3 patients (elective in 2), ablation was performed in 1 patient, and 1 patient received a pacemaker for brady-tachycardia syndrome. Two patients with ventricular tachycardia received an implantable cardioverter defibrillator.
DISCUSSION
REDEFINE is the largest randomized trial to study RAAS inhibition in RV dysfunction. Losartan had no significant treatment effect on RV EF, or on relevant secondary outcome parameters in rTOF with RV EF <50% and without severe residual valvular dysfunction.
Hypothesis
In the REDEFINE study, losartan effects were evaluated to (1) prevent RV deterioration in asymptomatic mild RV dysfunction, (2) prevent progressive RV failure in subgroups at risk, and (3) treat symptomatic RV failure. Inhibition of RAAS is beneficial in patients with LV dysfunction. 13 Because patients with RV dysfunction have similar neurohormonal activation, it could be hypothesized that RAAS inhibition would also be beneficial. 4, 14 Previous pilot studies in patients with ACHD also suggested beneficial hemodynamic effects on systemic RV dysfunction in symptomatic patients with transposition of the great arteries and in patients with rTOF with restrictive RV physiology and pulmonary regurgitation.
20,21
Mild RV Dysfunction
The lack of an overall treatment effect in our study on RV EF may be explained by several factors. (1) Most patients were classified as asymptomatic with mild RV dysfunction, with RV EF 40% to 50% and limited neurohormonal activation. Thus, our results indicate that losartan does not prevent RV deterioration in asymptomatic mild RV dysfunction during almost 2 years of follow-up. (2) Similar to a recent cohort study, RV function generally remained stable, suggesting little room for improvement in most patients. 37 (3) In many patients with ACHD, focal scar tissue attributable to surgical incisions or patches is thought to contribute to RV dysfunction, but losartan presumably has few or no effects on such scars. 21, 22, 24 
Subgroups at Risk
Only a few patients had moderate (<40%) RV dysfunction, and because of the limited statistical power for subgroup analyses, no definitive conclusions could be provided. In an exploratory analysis, however, a small but statistically significant benefit was found in patients with combined nonrestrictive RV and incomplete remodeling, present in about one third of patients. Incomplete RV remodeling after pulmonary Female sex, n (%) 12 (26) 18 (38) Pulmonary atresia+VSD, n (%) 4 (9) 4 (8)
Age at initial correction, y 2.4 (1.1-7.0) 3.2 (1.5-7.3)
Previous shunt procedure, n (%) 17 (36) 20 (42) Previous supraventricular tachycardia, n (%) 10 (21) 12 (25) Previous ventricular tachycardia, n (%) 1 (2) 4 (8) Pulmonary valve replacement, n (%) 28 (60) 32 (67) Previous use ACEi/ARB, n (%) 3 (6) 3 (6) β-Blocker use, n (%) 4 (9) 10 (21) Diuretics use, n (%) 2 (4) 1 (2) NYHA II, n (%) 8 (17) ACEi indicates angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CMR, cardiovascular magnetic resonance; NYHA, New York Heart Association; PR, pulmonary regurgitation; and VSD, ventricular septal defect. valve replacement, indicated by factors such as QRS fragmentation, is associated with ongoing RV deterioration, arrhythmias, and mortality. 23, 25, 26, 38, 39 The effects observed in this subgroup are therefore of clinical interest, to prevent progressive RV failure, but should be confirmed in future studies. The lack of benefit in restrictive RV physiology, in contrast to a previous study, 21 suggests that losartan may be inefficient in diastolic RV dysfunction. This observation is in line with the lack of benefit of RAAS inhibition in diastolic LV failure. ORIGINAL RESEARCH
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Symptomatic RV Failure
Finally, our study included only few (n=13 in analysis) symptomatic patients, partly because of the reluctance of treating cardiologists, although not evidence-based, to discontinue treatment with RAAS inhibition in these patients. In this small group, we observed favorable point estimates of losartan effects on biventricular function (+2.2% RV EF, +5.6% LV EF), similar to a study on angiotensin II receptor blockers in transposition of the great arteries. 20 These effects were not statistically significant because of the limited subgroup sample size, but at least do not rule out a clinically important benefit in patients with symptomatic RV failure.
Other Considerations
Similar to previous studies, losartan was tolerated well by most patients in the REDEFINE trial, although monitoring of renal and liver function parameters is warranted considering ≈10% risk of renal/liver dysfunction. 20, 27 The results of this trial are applicable to patients with rTOF who fulfilled criteria for this study, and should be only cautiously extrapolated to other groups with RV dysfunction.
Limitations
The REDEFINE trial had limitations as expected in randomized trials in the ACHD population. Limited patient numbers, low rate of hospitalization/death, and low participation rates were anticipated. Nonetheless, the REDEFINE trial was adequately powered for the primary outcome analysis. Considering the 95% CI, the treatment effect of losartan in comparison with placebo was between -1% and +2% RV EF, suggesting no clinically relevant effect. Our trial was further limited by the mean follow-up time of 21 months. Considering the relatively stable RV function during this trial follow-up duration, it is conceivable that a beneficial effect of losartan on RV dysfunction will 
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manifest after longer treatment duration. However, statistical power for subgroup analyses or clinical outcomes remained limited. In addition, only a few symptomatic patients were included. However, more stringent inclusion criteria would have resulted in an even smaller study. Yet, considering our results, future studies on pharmaceutical and other interventions may focus on the most severely affected patients, for which international collaboration seems warranted. 20, 21 Finally, results from a post hoc analysis in a subgroup of patients with nonrestrictive RV and incomplete remodeling should be interpreted with caution.
CONCLUSIONS
In the REDEFINE trial, losartan did not improve RV dysfunction or secondary outcome parameters in patients with rTOF. Therefore, RAAS inhibition should not be prescribed routinely in asymptomatic patients with mild RV dysfunction to prevent heart failure. Exploratory subgroup analysis suggested favorable effects of losartan in a vulnerable group with nonrestrictive RV and incomplete remodeling. Future studies should confirm if there might be a role for losartan in this subgroup and in symptomatic RV failure.
